Physician profile
Eric J Buchner
NPI 1245490697
$2,039.69
in general payments reported to CMS, 2019-2025
26 companies · $408 in 2025
The $408 reported for 2025 was more than what 75% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $48.73 · 2021: $240 · 2022: $221 · 2023: $311 · 2024: $367 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $561.61 | 2021-2025 | Xeomin |
| Abbvie INC. | $450.45 | 2022-2025 | Botox, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $187.72 | 2019 | |
| Nevro Corp. | $118.02 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $90.44 | 2019-2025 | Belbuca |
| Ipsen Biopharmaceuticals, INC | $83.06 | 2019-2025 | Dysport |
| Allergan, INC. | $80.64 | 2019-2020 | |
| Grt US Holding, INC. | $63.81 | 2022 | |
| Merz North America, INC. | $38.59 | 2019 | |
| Relievant Medsystems, INC. | $36.76 | 2022 | |
| Depuy Synthes Sales INC. | $36.13 | 2024 | Orthovisc |
| Pacira Pharmaceuticals Incorporated | $27.39 | 2025 | Iovera |
| Pfizer INC. | $24.08 | 2019 | |
| Si-Bone, INC. | $23.99 | 2024 | |
| Boston Scientific Corporation | $23.77 | 2024 | Intracept |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $22.08 | 2023 | Sprint Pns System |
| Electronic Waveform Lab, INC. | $21.77 | 2019-2023 | |
| Averitas Pharma INC. | $19.51 | 2023 | Qutenza |
| Kyowa Kirin, INC. | $18.93 | 2023 | Crysvita |
| Fidia Pharma USA INC. | $18.66 | 2024 | Hymovis, Hyalgan, Triluron |
| Axsome Therapeutics, INC. | $17.27 | 2025 | Symbravo |
| Daiichi Sankyo INC. | $16.58 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.10 | 2022 | |
| Scilex Pharmaceuticals INC. | $14.50 | 2019 | |
| International Rehabilitative Sciences, INC | $14.27 | 2025 | Rs-4i Plus With Intersperse |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Buchner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.